besifovir 150mg

DRUG2 trials

Sponsors

IlDong Pharmaceutical Co Ltd

Conditions

Chronic Hepatitis B

Phase 3

Phase 3 and Extensional Study of Besifovir

IlDong Pharmaceutical Co LtdChronic Hepatitis B

Start: 2013-10-31End: 2023-01-31Updated: 2020-01-27

Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues

CompletedNCT02792088

IlDong Pharmaceutical Co LtdChronic Hepatitis B

Start: 2015-07-31End: 2020-02-29Updated: 2023-02-21

Related Papers

Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy

Cancers2024-02-224 citations

Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial

Clinical and Molecular Hepatology2021-01-2517 citations

Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial

The American Journal of Gastroenterology2020-04-2922 citations

Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection

Clinical Gastroenterology and Hepatology2018-11-1558 citations